In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

This content is currently on FREE ACCESS, enjoy another 36 days of free consultation


Clinical correlates of epicardial or microvascular spasm assessed by intracoronary acetylcholine provocative testing among patients with non-obstructive coronary artery disease.

Session Poster Session 3

Speaker Marco Giuseppe Del Buono

Congress : Acute Cardiovascular Care 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Vasospasm
  • Session type : Poster Session
  • FP Number : P749

Authors : RA Montone (Rome,IT), MG Del Buono (Rome,IT), M Russo (Rome,IT), F Fracassi (Rome,IT), F Vergni (Rome,IT), M Camilli (Rome,IT), MC Meucci (Rome,IT), F Gurgoglione (Rome,IT), V Vetrugno (Rome,IT), G Niccoli (Rome,IT), F Crea (Rome,IT)


RA Montone1 , MG Del Buono1 , M Russo1 , F Fracassi1 , F Vergni1 , M Camilli1 , MC Meucci1 , F Gurgoglione1 , V Vetrugno1 , G Niccoli1 , F Crea1 , 1Polyclinic Agostino Gemelli, Department of Cardiovascular and Thoracic Sciences, Catholic University of the Sacred Heart, Rome, I - Rome - Italy ,


Background. Coronary vasomotor abnormalities at epicardial or microvascular level represent important mechanisms responsible for myocardial ischemia in patients with non-obstructive coronary arteries. Provocative test with intracoronary administration of acetylcholine (ACh) or ergonovine represents the gold standard for detection of vasomotor abnormalities.

Purpose. We evaluated if different clinical characteristics are associated to different responses at intracoronary provocative test. In particular, we compared clinical features of patients developing epicardial spasm or microvascular spasm.

Methods. We prospectively enrolled patients undergoing invasive coronary angiography with evidence of non-obstructive coronary arteries and receiving a provocative test with ACh or ergonovine for suspected vasomotor abnormalities. Only patients with a positive response at provocative test were included in the final analysis. Both patients with stable angina and patients presenting with acute coronary syndromes (ACS) were enrolled in our study.

Results. We included 119 patients [mean age 62.7±12.4 years, 57 (47.9%) male] presenting with non-obstructive coronary artery disease and with a positive response at invasive provocative test (68 patients with stable angina and 51 patients with ACS). Of note, patients with epicardial spasm compared with patients with microvascular spasm were more frequently smokers [24 (31.2%) vs 3 (7.1%), p=0.003)], had diffuse coronary atherosclerosis rather than normal coronary arteries [60 (77.9%) vs 20 (47.6%), p=0.003)], and had an ACS as clinical presentation [39 (50.6%) vs 12 (28.6%), p=0.03)]. On the other hand, patients with microvascular spasm presented more frequently diastolic dysfunction compared with patients with epicardial spasm [23 (54.7%) vs 32 (41.6%), p=0.045)].

Conclusions. Coronary vasomotor abnormalities represent an important cause of myocardial ischemia both in patients presenting with stable angina and in patients presenting with ACS. Of importance, our study demonstrated that specific clinical features are associated to different responses to intracoronary provocative test. In particular, epicardial spasm is more frequent in ACS patients, whereas microvascular spasm is more frequent in patients with stable angina and is associated with diastolic dysfunction.

This content is currently on FREE ACCESS, enjoy another 36 days of free consultation


Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are